(Q37875058)

24 August 2017

1 reference

title

Optimal management of metastatic colorectal cancer: current status (English)

1 reference

24 August 2017

1 reference

metastatic colon cancer

1 reference

1 reference

Autumn J McRee

1

1 reference

24 August 2017

Richard M Goldberg

series ordinal

2

1 reference

24 August 2017

publication date

1 May 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

71

1 reference

24 August 2017

issue

7

1 reference

24 August 2017

page(s)

869-884

1 reference

24 August 2017

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

5-Fluorouracil: mechanisms of action and clinical strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

21 January 2018

Capecitabine: a review

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

The evolution of fluoropyrimidine therapy: from intravenous to oral

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gas

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

5-fu metabolism in cancer and orally-administrable 5-fu drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic O

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

VEGF-targeted therapy: mechanisms of anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

Stop and Go FOLFOX plus Bevacizumab Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

The continuum of care: a paradigm for the management of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591770-000000000-00000

Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer

21 January 2018

1 reference

12 December 2020

Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.

1 reference

12 December 2020

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

1 reference

12 December 2020

Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer

1 reference

12 December 2020

Phase I-II trial of high-dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer.

1 reference

12 December 2020

UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan

1 reference

12 December 2020

Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid

1 reference

12 December 2020

Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas

1 reference

12 December 2020

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study

1 reference

12 December 2020

Phase II trial of irinotecan in patients with metastatic colorectal carcinoma

1 reference

12 December 2020

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

1 reference

12 December 2020

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1 reference

12 December 2020

Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study

1 reference

12 December 2020

Adjuvant therapy for colon cancer

1 reference

12 December 2020

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

1 reference

12 December 2020

Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.

1 reference

12 December 2020

[Modulation of 5-fluorouracil with folinic acid in advanced colorectal cancers. Groupe d'étude et de recherche sur les cancers de l'ovaire et digestifs (GERCOD)]

1 reference

12 December 2020

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy

1 reference

12 December 2020

A comprehensive pathway map of epidermal growth factor receptor signaling

1 reference

12 December 2020

Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with high-dose folinic acid: a pilot study

1 reference

12 December 2020

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

12 December 2020

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project

1 reference

12 December 2020

10.2165/11591770-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

24 August 2017

1033546917

0 references

1 reference